Astrazeneca Share Price (AZN)

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Astrazeneca Plc	LSE:AZN	London	Ordinary Share	GB0009895292	ORD SHS $0.25

	Price Change	% Change	Share Price	Shares Traded	Last Trade
	117.00	1.61%	7,392.00	424,227	12:17:30

Bid Price		Offer Price	High Price	Low Price	Open Price
7,393.00		7,394.00	7,399.00	7,256.00	7,270.00

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Pharmaceuticals & Biotechnology	17,322.09	1,562.83	133.31	55.9	96,967

Last Trade Time	Trade Type	Trade Size	Trade Price	Currency
12:17:23	AT	18	7,392.00	GBX

Related Shares
Glaxosmithkline (GSK), Hikma Pharmaceuticals (HIK), Geiger Counter (GCS), Valirx (VAL)

Astrazeneca (AZN) Latest News

Astrazeneca News

Date	Time	Source	Headline
12/11/2019	08:56	ALNC	Astra's Anifrolumab Shows Advantage Across Various Efficacy Endpoints
12/11/2019	07:07	ALNCF	Alliance News Flash Headline
12/11/2019	07:01	UKREG	AstraZeneca PLC Anifrolumab demonstrated superiority in TULIP 2
11/11/2019	08:07	ALNC	TOP NEWS: AstraZeneca Reports Positive Test Results For Anaemia Drug
11/11/2019	07:00	UKREG	AstraZeneca PLC Roxadustat pooled analyses: no increased CV risk
08/11/2019	20:19	DJN	FibroGen, AstraZeneca Up After Roxadustat Data
08/11/2019	08:14	ALNC	AstraZeneca Drug Roxadustat Increases Haemoglobin Levels In Two Trials
08/11/2019	07:48	DJN	AstraZeneca Finds Increased Hemoglobinin in Roxadustat Phase 3 Trial
08/11/2019	07:00	UKREG	AstraZeneca PLC Roxadustat significantly increased haemoglobin
06/11/2019	14:55	ALNC	UPDATE: AstraZeneca To Present Encouraging Data From Calquence Trial

More Astrazeneca News

Astrazeneca Takeover Rumours

Astrazeneca (AZN) Share Charts

1 Year Astrazeneca Chart

1 Month Astrazeneca Chart

Intraday Astrazeneca Chart

Astrazeneca (AZN) Discussions and Chat

Astrazeneca Forums and Chat

Date	Time	Title	Posts
13/11/2019	09:30	AstraZeneca	2,309
26/8/2019	09:24	Alzheimer's can be caught .... It's a transmissible disease	103
01/5/2019	18:48	why the fall	-
13/2/2019	11:48	AstraZeneca Full Year Results on Thursday	-
15/10/2018	17:31	* AstraZeneca *	360

Add a New Thread

Astrazeneca (AZN) Most Recent Trades

Trade Time	Trade Price	Trade Size	Trade Value	Trade Type
12:17:23	7,392.00	18	1,330.56	AT
12:17:23	7,392.00	152	11,235.84	AT
12:17:23	7,392.00	13	960.96	AT
12:17:23	7,392.00	32	2,365.44	AT
12:16:58	7,391.00	136	10,051.76	AT

View all Astrazeneca trades in real-time

Astrazeneca (AZN) Top Chat Posts

Date	Subject
13/11/2019 08:20	Astrazeneca Daily Update: Astrazeneca Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker AZN. The last closing price for Astrazeneca was 7,275p. Astrazeneca Plc has a 4 week average price of 6,670p and a 12 week average price of 6,670p. The 1 year high share price is 7,646p while the 1 year low share price is currently 5,312p. There are currently 1,311,776,898 shares in issue and the average daily traded volume is 1,943,626 shares. The market capitalisation of Astrazeneca Plc is £96,940,312,762.20. Read Full Thread Reply
01/10/2019 07:30	arja: cheshire pets, sorry for delay in answering as I was abroad for a few days . It just means " no overhead resistance" when a share price breaks through to a higher level not seen previously . I notice AZN down in last day or so with disappointing announcement and share prices of drug companies can be volatile I guess as a lot of news flows . i am not sure if USA or UK is LEAD market for this stock . Read Full Thread Follow Reply
14/8/2019 06:16	ayl30: RNS today looks positive. Should help share price trend continue Read Full Thread Follow Reply
18/6/2019 12:01	bluemango: Meanwhile, share price only needs to put on just over 2% more and it will be surpassing all time high of £65.40. Good trials results and new approvals keep flowing through and should eventually be translated into earnings and dividend growth. Read Full Thread Follow Reply
18/7/2018 11:01	bountyhunter: http://uk.advfn.com/stock-market/london/astrazeneca-AZN/share-news/AstraZeneca-Increases-Drug-Stockpile-in-Preparatio/77885692 that's one way to reduce any potential initial WTO tariffs/bottlenecks! Read Full Thread Follow Reply
08/10/2017 11:51	cool druid: [...] Merrill Lynch Ups Motif Bio Stake Following Iclaprim Results (ALLISS) By Alliance \| Fri, 6th October 2017 - 14:19 LONDON (Alliance News) - Merrill Lynch International has raised its stake Motif Bio PLC under a transaction on Wednesday and now holds 5.038% interest in the pharmaceutical company. The purchase came on the same day Motif Bio reported positive results from its phase III clinical study of flagship antibiotic Iclaprim. Iclaprim met its primary endpoint in the phase III trial in patients with acute bacterial skin and skin structure infections, which was non-inferiority whilst compared to the standard of care vancomycin. Earlier today, Motif Bio released new pre-clinical data showing positive results regarding the use of Iclaprim. In an in vivo model mimicking the pathophysiology observed in cystic fibrosis patients, rats were dosed with either 80 or 60 milligrams of Iclaprim, 50 mg of Vancomycin, and a placebo. The Iclaprim rats showed a 100% survival rate, 33 out of 33, while Vancomycin showed 92% survival rate and the placebo 48%. Merrill Lynch had a holding that was below the notable threshold prior to the purchase. Motif Bio shares were up 6% on Friday at 46.11 pence. By Joshua Warner; joshuawarner@alliancenews.com; @JoshAlliance Read more: http://www.thisismoney.co.uk/money/investing/article-4955948/Advanced-Oncotherapy-enjoys-64-share-price-boost.html#ixzz4uoWb91d9 A step ahead of ImmuPharma is Motif Bio, which has successfully completed not one, but two phase III clinical trials and is preparing to submit its antibiotic, iclaprim, for regulatory sign-off. While the shares are up 23 per cent this week at around 43p, analysts think it could be worth double that figure. Amphion Innovations, the investment group, owns just over 14 per cent of Motif. Its chief executive thinks market hasn’t quite grasped how valuable this shareholding is. He might be right as Amphion’s market capitalisation is some way short of the value of its Motif investment Read Full Thread Follow Reply
30/7/2017 18:12	nw99: Finally, Sabah Meddings, writing for Sunday Times' 'Inside The City' column, looked at AstraZeneca, with a share price that plunged last week after it revealed its key 'Mystic' cancer drug trial had produced disappointing results.The drugmaker had tried its best to deflect the bad news by highlighting ann $8.5bn partnership with Merck over its Lynparza cancer treatment, as well as positive phase III results for another of its cancer candidates Tagrisso.But investors were having none of it, wiping £10bn off the value of AstraZeneca in a single day.Meddings suggested the City may have overreacted, however, saying the crash could have been exacerbated by uncertainty over the future of the company's chief Pascal Soriot, and pointing out Neil Woodford's decision to continue to back Astra over rival GlaxoSmithKline.Woodford had noted that Astra remained "very attractive" - comments backed up by Citi's 'buy' rating on the stock.Meddings said Astra's shares looked cheap compared to GSK at 22 times earnings - about half of Glaxo's valuation - but added that Astra's value wasn't wildly different to the rest of the sector globally.She said that - Mystic aside - the results were "OK", as revenue fell 11% to $10.5bn in the first half, in line with expectations, and profits still leaping 22% to $1.8bn even after accounting for weak sterling.Meddings said it would take time for other projects to emerge from the lab in an investable state, although ongoing speculation of a potential bid from Novartis would likely "keep a floor" on Astra's price."Therefore, Astra looks like a reasonable each-way bet - and one that pays a dividend." Read Full Thread Follow Reply
28/7/2017 14:10	minerve: My comment from yesterday: "Minerve 27 Jul '17 - 10:46 - 1954 of 1988 0 0 Edit This is oversold IMO. Just looking at TPs, consensus affects on earnings and past share price history I would say a stabilising share price should sit around 4675." Pretty good, huh? Read Full Thread Follow Reply
27/7/2017 09:46	minerve: This is oversold IMO. Just looking at TPs, consensus affects on earnings and past share price history I would say a stabilising share price should sit around 4675. Read Full Thread Follow Reply
27/7/2017 09:10	steeplejack: Well,I guess the analysts have run their adjustments of new discounted cash flow calculations on Mystic accounting for this giant setback/failure.The share price has retreated back to where it was end Feb.A correction of 15% on the day,is fairly unforgiving but understandable.I'm not selling but I'm unprepared to buy into a dead cat bounce or the wishful thinking of a bid.For now,there's consolation in the dividend. Read Full Thread Follow Reply
02/5/2014 07:43	harvester: Share price below indicative offer since not all cash offer and risk of pfizer share price weakening as well as risk of the deal failing . AZN share price closed last night at 4851 up 151 based on suspicious after hours trades . At normal market close the share price was 4676.5 . Big money at stake. Hence bound to be some insider trading going on . Read Full Thread Follow Reply

Astrazeneca share price data is direct from the London Stock Exchange

Your Recent History

LSE

AZN

Astrazenec..

Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US Finance Manila

P: V: D:20191113 12:32:38